Assessment of pharmacokinetic interaction between gefapixant (MK‐7264), a P2X3 receptor antagonist, and the OATP1B1 drug transporter substrate pitavastatin
…, B Ma, GC Garrett, R Evers, JE Laabs… - Clinical …, 2022 - Wiley Online Library
Gefapixant (MK‐7264, AF‐219), a first‐in‐class P2X3 antagonist, is being developed as oral
treatment for refractory or unexplained chronic cough. Based on in vitro data, gefapixant …
treatment for refractory or unexplained chronic cough. Based on in vitro data, gefapixant …
Abstract CT125: Evaluation of potential drug-drug interactions (DDIs) between futibatinib and CYP3A inhibitors/inducers, CYP3A substrates, or proton pump inhibitors …
I Yamamiya, J Laabs, A Hunt, T Takenaka… - Cancer Research, 2021 - AACR
Background Futibatinib is an oral, irreversible FGFR1-4 inhibitor with clinical activity in
cholangiocarcinoma and other FGFR-aberrant tumors. The recommended futibatinib dosage is 20 …
cholangiocarcinoma and other FGFR-aberrant tumors. The recommended futibatinib dosage is 20 …
Dye exclusion as a means to measure wetness protection of human skin
M Tate, G Grove, R Joch, J Laabs… - Skin Research and …, 2007 - Wiley Online Library
Background/purpose: Excessive skin hydration from occlusive coverings such as absorbent
articles, bandages, etc. has been known to compromise the skin's barrier properties. …
articles, bandages, etc. has been known to compromise the skin's barrier properties. …
[PDF][PDF] Evaluation of potential drug–drug interactions between futibatinib and CYP3A inhibitors/inducers, CYP3A substrates, or proton pump inhibitors
I Yamamiya, J Laabs, A Hunt… - Proceedings of the …, 2021 - metaballcreative.com
Background • Futibatinib is an oral, highly selective, and irreversible fibroblast growth factor
receptor (FGFR) 1–4 inhibitor with clinical activity in patients with advanced FGFR-aberrant …
receptor (FGFR) 1–4 inhibitor with clinical activity in patients with advanced FGFR-aberrant …
Temporal correspondence between pluvial lake highstands in the southwestern US and Heinrich Event 1
Pluvial lakes were abundant in the southwestern United States during Pleistocene glaciations,
particularly in the Great Basin. Many of these lakes occupied closed basins; therefore, …
particularly in the Great Basin. Many of these lakes occupied closed basins; therefore, …
[PDF][PDF] Effect of futibatinib on QT/QTc interval: a randomized, controlled, double-blind study.
I Yamamiya, J Laabs, D Sonnichsen… - Presented at the …, 2021 - metaballcreative.com
CT128 Page 1 References 1. Sootome H, et al. Cancer Res. 2020;80:4986–97. 2. Bahleda R,
et al. Ann Oncol. 2020;31:1405–12. 3. Meric-Bernstam F, et al. Oral presentation at: AACR …
et al. Ann Oncol. 2020;31:1405–12. 3. Meric-Bernstam F, et al. Oral presentation at: AACR …
Genotype–phenotype relations in primary familial brain calcification: systematic MDSGene review
…, V Dobricic, D Alvarez‐Fischer, BH Laabs… - Movement …, 2021 - Wiley Online Library
This systematic MDSGene review covers individuals with confirmed genetic forms of
primary familial brain calcification (PFBC) available in the literature. Data on 516 (47% men) …
primary familial brain calcification (PFBC) available in the literature. Data on 516 (47% men) …
A hexanucleotide repeat modifies expressivity of X‐linked dystonia parkinsonism
Objective X‐linked dystonia parkinsonism (XDP) is a neurodegenerative movement disorder
caused by a single mutation: SINE‐VNTR‐Alu (SVA) retrotransposon insertion in TAF1. …
caused by a single mutation: SINE‐VNTR‐Alu (SVA) retrotransposon insertion in TAF1. …
Basal Ganglia Atrophy as a Marker for Prodromal X‐linked Dystonia‐Parkinsonism
In neurodegenerative diseases, the characterization of the prodromal phase is essential for
the future application of disease‐modifying therapies. X‐linked dystonia‐parkinsonism is a …
the future application of disease‐modifying therapies. X‐linked dystonia‐parkinsonism is a …
Gefapixant does not have meaningful drug interactions with a MATE1/2K inhibitor or an OATP1B substrate
…, J Mccrea, A Hussain, R Evers, B Ma, J Laabs… - 2020 - Eur Respiratory Soc
Gefapixant (MK-7264) is a P2X3 receptor antagonist in development for refractory or unexplained
chronic cough. In vitro, gefapixant is a substrate of the renal efflux transporters MATE1 …
chronic cough. In vitro, gefapixant is a substrate of the renal efflux transporters MATE1 …